Pfizer Inc. (NYSE:PFE) Stock Holdings Boosted by Plan Group Financial LLC

Plan Group Financial LLC boosted its position in Pfizer Inc. (NYSE:PFE) by 14.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 35,789 shares of the biopharmaceutical company’s stock after purchasing an additional 4,472 shares during the quarter. Plan Group Financial LLC’s holdings in Pfizer were worth $949,000 at the end of the most recent quarter.

Several other hedge funds have also recently bought and sold shares of the company. Swedbank AB grew its position in Pfizer by 0.7% in the 3rd quarter. Swedbank AB now owns 5,745,831 shares of the biopharmaceutical company’s stock valued at $166,284,000 after buying an additional 37,636 shares in the last quarter. New Century Financial Group LLC bought a new position in shares of Pfizer in the third quarter valued at approximately $202,000. Vest Financial LLC increased its stake in shares of Pfizer by 200.3% during the third quarter. Vest Financial LLC now owns 23,661 shares of the biopharmaceutical company’s stock valued at $685,000 after acquiring an additional 15,781 shares during the period. Northwest Investment Counselors LLC bought a new stake in Pfizer during the third quarter worth approximately $103,000. Finally, Copeland Capital Management LLC bought a new stake in Pfizer during the third quarter worth approximately $144,000. 68.36% of the stock is currently owned by institutional investors.

Pfizer Stock Up 0.1 %

Shares of Pfizer stock opened at $25.56 on Wednesday. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock has a 50-day moving average price of $26.26 and a 200 day moving average price of $27.46. The company has a market cap of $144.82 billion, a P/E ratio of 18.12, a P/E/G ratio of 0.63 and a beta of 0.64.

Pfizer (NYSE:PFE) last posted its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. As a group, analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. The ex-dividend date is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.73%. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s payout ratio is 121.99%.

Wall Street Analysts Forecast Growth

PFE has been the subject of a number of research reports. Evercore ISI raised Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. StockNews.com cut Pfizer from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, November 20th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research report on Wednesday, October 23rd. Truist Financial reduced their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a research report on Wednesday, December 18th. Finally, UBS Group dropped their target price on shares of Pfizer from $31.00 to $29.00 and set a “neutral” rating on the stock in a report on Wednesday, January 8th. One analyst has rated the stock with a sell rating, eight have given a hold rating, six have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer currently has an average rating of “Moderate Buy” and an average target price of $31.92.

Insiders Place Their Bets

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 0.06% of the company’s stock.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.